查詢結果分析
來源資料
相關文獻
- 消化性潰瘍的元兇--幽門螺旋桿菌
- 醇提大黃對消化性潰瘍合併幽門螺旋桿菌感染之作用探討
- 幽門螺旋桿菌根除治療對消化性潰瘍復發的效益評估
- C丨 Urea Breath Test Combined with Symptomatology is Helpful in Deciding Which Dyspeptic Patients Need Endoscopy to Rule in Peptic Ulcer
- Current Treatment of Helicobacter Pylori Infection and Peptic Ulcer Disease
- Omeprazole Plus Amoxicillin Versus Triple Therapy Eradicates Helicobacter Pylori in the Chinese with Peptic Ulcer Disease
- 幽門螺旋桿菌與消化性潰瘍--根除療法與治療指南
- Patient Factors Affecting Helicobacter Pylori Eradication Therapy
- 消化性潰瘍疾病與幽門螺旋桿菌
- 幽門螺旋桿菌與消化性潰瘍致病機轉之關係
頁籤選單縮合
題 名 | 幽門螺旋桿菌根除治療對消化性潰瘍復發的效益評估=An Evaluation of the Effects of Helicobacter Pylori Eradicated Therapy on the Recurrence of Peptic Ulcer |
---|---|
作 者 | 劉宜廉; 李龍騰; | 書刊名 | 中華民國家庭醫學雜誌 |
卷 期 | 8:4 1998.12[民87.12] |
頁 次 | 頁181-191 |
分類號 | 415.526 |
關鍵詞 | 幽門螺旋桿菌; 消化性潰瘍; Peptic ulcer; Ulcer recurrence; Helicobacter pylori; Eradication; |
語 文 | 中文(Chinese) |
中文摘要 | 傳統的消化性潰瘍治療雖然可以治療潰瘍,但是治癒後一年內的潰瘍復發率甚高(64%至100%)。近幾年來,由於幽門螺旋桿菌的被發現,對於消化性潰瘍的成因和治療有了革命性的見解,經由抗生發現素單一療程治療以根除幽門螺旋桿菌,比持續使用制酸劑更能有效的預防潰瘍的復發。本研究旨在探討消化性潰瘍併有幽門螺旋桿菌感染的病患,接受根除治療與否和潰瘍的復發情形及探討其相關的危險因子。本研究的個案來源係取自1995整年於某醫學中心就診的病患,經証實有消化性潰瘍併有幽門螺旋桿菌感染者,收集其基本資料、接受治療的方式、治療後潰瘍是否復發,及其他因素如吸菸、喝酒、合併疾病和併用藥物等相關資料。結果發現,接受根除治療的356位和接受非根除治療的72位病患,一年內的潰瘍復發率各為36.2%及72.2%。在影響潰瘍復發的多變項邏輯迴歸分析中,發現潰瘍的復發和接受根除治療與否及幽門螺旋桿菌是否被根除皆有顯著的相關性(勝算比各為4.26及6.36),而和性別、年齡、吸菸、飲酒習慣、潰瘍類別、合併疾病及併用藥物等因素不具顯著相關性。本研究發現消化性潰瘍病患如果接受幽門螺旋桿菌根除治療,能有效的預防潰瘍的復發。 |
英文摘要 | Although the conventional ulcer therapy could heal peptic ulcer, high recurrence rates (64-100%) have been reported during the first year of follow-up of patients who were receiving treatment. Helicobacter pylori (H. pylori) burst on the scene a few years ago, it revolutionised views on the etiology and treatment of peptic ulcer. The recurrence of ulcers can be more effectively prevented by a single course of antimicrobial treatment that eradicates H. pylori infection than by the continuous suppression of acid secretion. The purposes of this study were to investigate the relation between ulcer recurrence and eradicated therapy and to determine risk factors of ulcer recurrence. There were 428 peptic ulcer patients infected with H. pylori, who were collected from a medical center in 1995 received either dural/triple therapy (n = 356) or non-eradicated therapy (n = 72) in our study. The ulcer recurrence rate in the dural/triple therapy group (36.2%) was significantly lower than that of the non-eradicated therapy group (72.2%) (p ≦ 0.001). Significant variables in the multivariate logistic regression model for ulcer recurrence rate are eradicated therapy and H. pylori status (odds ratio = 4.26 and 6.36, p ≦ 0.0001 respectively) There was not any significant interaction between ulcer recurrence and sex, age, type of ulcer, smoking, drinking, comorbidity or non-steroid anti-inflammatory drugs used. The study concludes that ulcer recurrence could be significantly reduced by using eradicated therapy. |
本系統中英文摘要資訊取自各篇刊載內容。